



Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting

Phase 2a Data Suggest Advantages of Lead Agent VT-1161 over Current Antifungal Therapies

Full Enrollment of Ongoing Phase 2b Trial in Onychomycosis Expected in Fourth Quarter of 2015

July 15, 2015, Research Triangle Park, North Carolina – [Viamet Pharmaceuticals, Inc.](#) today announced that data from a Phase 2a study of VT-1161, the Company's lead novel, oral antifungal compound, will be presented at the American Podiatric Medical Association 2015 Annual Scientific Meeting, to be held from July 23-26, 2015, in Orlando, FL. In addition, the company will also provide an update on the ongoing RENOVATE (REstoring Nail; an Oral VT-1161 Tablet Evaluation) study, a Phase 2b clinical trial of VT-1161 for the oral treatment of toenail fungal infection, also known as onychomycosis.

Thorsten Degenhardt, Ph.D., Viamet's Vice President of Project Management, will present, "Efficacy and Safety of Oral VT-1161, a Novel and Selective Inhibitor of Fungal CYP51, in a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study (NCT01891305) in Patients with Moderate-to-Severe Interdigital Tinea Pedis." This study demonstrated the potent antifungal activity and robust safety profile of oral VT-1161 in the treatment of tinea pedis, or athlete's foot, a very common skin condition and a clinical model for fungal nail infection.

"We are very excited to be among a select group of companies chosen for an oral presentation at this prestigious conference. We believe that VT-1161 has the potential to be a significant new treatment option for the treatment of fungal infections of the skin and nail, including onychomycosis," commented Robert Schotzinger, MD, PhD, CEO of Viamet. "We are also pleased to announce that our ongoing RENOVATE Phase 2b clinical trial in onychomycosis has surpassed 50% enrollment, and we remain on track to fully enroll the study in the fourth quarter of 2015. Based on data generated to date, we believe that VT-1161 will prove to be a safer and more effective therapy for onychomycosis than current oral medications and will markedly outperform current topical therapies in efficacy outcomes."

About Onychomycosis

Onychomycosis is a fungal infection that involves the nail matrix, nail bed, and nail plate. Onychomycosis can cause discoloration, thickening and splitting of the nail, as well as separation of the nail plate from the nail bed. The condition may result in pain when walking, thereby limiting ambulation. The abnormal appearance of the infected nails and the perception that there is an active and contagious infection is a significant concern for many patients. An estimated 32 million individuals in the United States suffer from this condition.

About VT-1161

VT-1161 is a potent and selective, orally-administered inhibitor of fungal CYP51. VT-1161 blocks the production of ergosterol, an essential component of the fungal cell membrane. In *in vitro* and *in vivo* studies, VT-1161 has demonstrated broad spectrum activity against both dermatophytes and *Candida* species,

including those species that cause onychomycosis and recurrent vulvovaginal candidiasis (RVVC). Because VT-1161 is highly selective for fungal CYP51, the Company believes that it may avoid the side effects that limit the use of commonly prescribed oral antifungal therapies, such as liver toxicity and drug-drug interactions.

About Viamet (www.viamet.com)

Viamet is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on a proprietary metalloenzyme chemistry platform. The Company is using this platform to design drugs that are expected to have greater selectivity and safety as well as improved potency compared to currently available therapies. The Company's initial product candidates include a portfolio of highly potent and selective novel antifungal agents. Additional programs in oncology and orphan diseases are ongoing which leverage the Company's expertise in metalloenzymes.

Contact:

Richard Katz, M.D., Chief Business and Financial Officer
Viamet Pharmaceuticals, Inc.
4505 Emperor Boulevard, Suite 300
Durham, North Carolina, USA 27703
Telephone: +919.467.8539 ext. 316

This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet's business and VT-1161, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies is based in the Research Triangle Park region of North Carolina, USA.